deltatrials

Metastatic pancreatic adenocarcinoma Trials in St. Louis, United States

Conditions / Metastatic pancreatic adenocarcinoma / St. Louis, United States

Metastatic pancreatic adenocarcinoma is a medical condition with active clinical research programs worldwide.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID Title Status Phase
NCT04548752 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations ACTIVE_NOT_RECRUITING
NCT04548752 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations ACTIVE_NOT_RECRUITING
NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer COMPLETED PHASE3
NCT02826486 Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients COMPLETED PHASE2
NCT04548752 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations ACTIVE_NOT_RECRUITING
NCT04233866 Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread ACTIVE_NOT_RECRUITING PHASE2
NCT06998940 Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations RECRUITING PHASE3
NCT01959139 S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer COMPLETED PHASE1/PHASE2
NCT04548752 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations ACTIVE_NOT_RECRUITING
NCT02890355 FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer ACTIVE_NOT_RECRUITING PHASE2

Related Pages